March 16, 2017
USPTO favorable to Ceylad
The U.S. Patent and Trademark Office (USPTO) has been favorable to Ceylad for the fourth time for production of Allogenic TCR-Deficient CAR-T cells.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
March 16, 2017
Millenium Dental Technologies reached FDA clearance for True Regeneration milestone
Millennium Dental Technologies, Inc. has reached milestone today in the one-year anniversary of the world’s first and only US FDA clearance for full-mouth True Periodontal Regeneration.
March 15, 2017
Severe asthma market is driving Nucala sales, opportunity for Teva, AstraZeneca, Sanofi, and Regeneron
Decision Resources Group (DRG) finds that Nucala’s novel mechanism of action and specific indication for eosinophilic asthma are key drivers behind the agent’s recent success in the severe asthma market.
March 15, 2017
InDex Pharmaceuticals gets patent grant in USA
Sweden-based pharmaceutical development company focusing on immunological diseases InDex Pharmaceuticals Holding AB has been granted a patent covering 19 compounds from the company’s DIMS platform by the United States Patent and Trademark Office (USPTO).
March 14, 2017
Market analyst puts focus on four major players in the Drug Manufacturers space
Ahead of Tuesday’s trading session, Stock-Callers.com puts focus on four major players in the Drug Manufacturers space.
March 14, 2017
Private companies AMO Pharma, Renedis Pharmaceutical team up to develop RND-001 for rare genetic diseases
AMO Pharma Limited and Ranedis Pharmaceuticals,two privately held U.S. pharma companies have partnered up to develop RND-001 for rare genetic diseases, including certain lysosomal storage disorders and other diseases affecting the central nervous system.
March 14, 2017
Innovative treatments and therapies from cannabis industry
The expansion of product lines and enhanced product development are fueling rising revenues and overall growth in the swelling cannabis market despite recent ambiguous reports of direction of the federal impact on the legal marijuana market
March 14, 2017
FDA OK’s Novartis’s breast cancer drug
The US Food and Drug Administration (FDA) has approved Novartis’s Kisqali (ribociclib, formerly known as LEE011) in combination with an aromatase inhibitor as initial endocrine-based therapy for treatment of postmenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.
March 13, 2017
Mylan, Genentech, Hoffmann-La Roche settle over Herceptin
Mylan has agreed to the terms of a global settlement with Genentech, Inc. and F. Hoffmann-La Roche Ltd. related to patents for Herceptin (trastuzumab), which provides Mylan with global licenses for its trastuzumab product.
March 13, 2017
Biotechnology companies stocks report
iShares NASDAQ Biotechnology exchange-traded fund has gained 13% so far this year, more than double the SPDR S&P 500 ETF’s 6.3% rise, as the potential for new drugs and mergers and acquisitions has rekindled interest in the beaten-down sector.